NASDAQ:CNTB Connect Biopharma Q1 2026 Earnings Report $2.48 +0.03 (+1.18%) As of 10:18 AM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Connect Biopharma EPS ResultsActual EPS-$0.34Consensus EPS -$0.29Beat/MissMissed by -$0.05One Year Ago EPSN/AConnect Biopharma Revenue ResultsActual Revenue$0.02 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConnect Biopharma Announcement DetailsQuarterQ1 2026Date5/12/2026TimeBefore Market OpensConference Call DateTuesday, May 12, 2026Conference Call Time9:00AM ETUpcoming EarningsConnect Biopharma's Q2 2026 earnings is estimated for Thursday, May 21, 2026, based on past reporting schedulesConference Call ResourcesPress Release (6-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(6-K)Quarterly report(10-Q) Connect Biopharma Earnings HeadlinesConnect Biopharma (CNTB) Expected to Announce Quarterly Earnings on ThursdayMay 14 at 1:53 AM | americanbankingnews.comConnect Biopharma to Present at the H.C. Wainwright 4th Annual BioConnect Investor ConferenceMay 12 at 4:05 PM | globenewswire.comRead this or regret it foreverThree Nobel Prize Winners expose this once-in-a-generation wealth shift: “Don’t Say I Didn’t Warn You” Porter Stansberry exposes how the convergence of three immense forces is about to rewrite everything about the American way of life: how you work, save, invest… it’s all about to change.May 14 at 1:00 AM | Porter & Company (Ad)Connect Biopharma Reports First Quarter 2026 Financial Results and Provides Business UpdateMay 12 at 9:00 AM | globenewswire.comConnect Biopharma: New Market Opportunity In The Emergency SettingApril 29, 2026 | seekingalpha.comConnect Biopharma Announces Enrollment in Phase 2 Seabreeze STAT Studies Will Continue as Planned Following Pre-Specified Interim AnalysisApril 23, 2026 | globenewswire.comSee More Connect Biopharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Connect Biopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Connect Biopharma and other key companies, straight to your email. Email Address About Connect BiopharmaConnect Biopharma (NASDAQ:CNTB) Holdings Ltd. is a clinical-stage biopharmaceutical company focused on the discovery and development of monoclonal antibody therapies for immune-mediated disorders. Headquartered in Singapore with a research and commercial presence in the United States, the company applies proprietary technology platforms to target novel pathways in inflammatory and autoimmune diseases. The company’s lead product candidate, CBP-201, is a fully human monoclonal antibody that antagonizes the interleukin-31 receptor, a key mediator of chronic pruritus in conditions such as atopic dermatitis and prurigo nodularis. A second clinical-stage program, CBP-701, selectively inhibits signaling through tumor necrosis factor receptor 1 (TNFR1), a strategy designed to preserve beneficial TNFR2 activity while reducing the risk of systemic immunosuppression. Together, these candidates reflect Connect Biopharma’s commitment to developing differentiated therapies with potentially improved safety and efficacy profiles. Since its founding in 2015, Connect Biopharma has advanced its pipeline through early-phase clinical trials and established strategic partnerships to support long-term development goals. The company completed its initial public offering on the Nasdaq Global Market under the ticker CNTB in 2021, raising capital to fund ongoing studies and expand its research capabilities. Its clinical programs are being evaluated across multiple geographies, including North America and the Asia-Pacific region. Connect Biopharma is led by an executive team and board of directors with extensive experience in biotechnology, pharmaceutical development and commercialization. Leveraging a blend of scientific rigor and clinical expertise, the management group aims to bring novel immunology treatments to patients with high unmet medical need.View Connect Biopharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Nebius Upside Expands as AI Feedback Loop IntensifiesOklo Stock Could Be Ready for Another Massive RunD-Wave Earnings Looked Weak, But Investors May Be Missing ThisChime Finally Turns Profitable—But Risks RemainHow Berkshire’s New York Times Bet Looks TodayPlug Power Flips The Switch On ProfitabilityHims & Hers Stock Plunges After Q1 Miss: Is the GLP-1 Pivot Enough to Fuel a Recovery? Upcoming Earnings Mizuho Financial Group (5/15/2026)Palo Alto Networks (5/19/2026)Home Depot (5/19/2026)Keysight Technologies (5/19/2026)Analog Devices (5/20/2026)Intuit (5/20/2026)NVIDIA (5/20/2026)Lowe's Companies (5/20/2026)Medtronic (5/20/2026)Target (5/20/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
